间充质干细胞来源外泌体在肝纤维化中的治疗机制  

Research of mesenchymal stem cell-derived exosomes in the treatment of liver fibrosis

作　　者：李光宇[1] 周庆[1] 李宏达 江宇航 徐三荣[1] LI Guangyu;ZHOU Qing;LI Hongda;JIANG Yuhang;XU Sanrong(Department of Hepatobiliary,Pancreatic and Splenic Surgery,Affiliated Hospital of Jiangsu University,Zhenjiang,Jiangsu 212000,China;Department of General Surgery,Affiliated Hospital of North China University of Science and Technology,Tangshan,Hebei 063000,China)

机构地区：[1]江苏大学附属医院肝胆胰脾外科,江苏镇江212000 [2]华北理工大学附属医院普外科,河北唐山063000

出　　处：《安徽医药》2025年第4期641-647,共7页Anhui Medical and Pharmaceutical Journal

基　　金：镇江市重点研发计划(社会发展)项目(SH2020027)。

摘　　要：肝纤维化以瘢痕形成为特征,是由慢性肝损伤向肝癌转变的中间病理过程。间充质干细胞(mesenchymal stem cells,MSCs)具备多向分化潜能,可参与多种疾病的损伤修复过程。MSCs来源的外泌体治疗肝纤维化是一种新兴的治疗方式,具备传统MSCs移植治疗的优点。目前较多研究关注于分析MSCs外泌体所含成分对于肝纤维化的治疗机制,其在细胞实验及动物实验中已取得一定成果。以MSCs外泌体为主的无细胞疗法是未来肝纤维化治疗的研究趋势。Hepatic fibrosis,characterized by scar formation,is an intermediate pathological process from chronic liver injury to liver cancer.Mesenchymal stem cells(MSCs),possessing multi-directional differentiation potential,can participate in the repair process of various diseases.MSCs-derived extracellular vesicles(MSCs-Ex)have emerged as a novel therapeutic approach for the treatment of liver fibrosis,with advantages over traditional MSCs transplantation.Currently,many studies focus on analyzing the therapeutic mechanism of MSCs-Ex in liver fibrosis by identifying its components,and some progress has been made in cell and animal experiments.Cellfree therapy based on MSCs-Ex is a research trend for the treatment of liver fibrosis in the future.

关 键 词：肝纤维化 间充质干细胞 外泌体 无细胞疗法 治疗机制 

分 类 号：R32[医药卫生—人体解剖和组织胚胎学]